A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

被引:93
|
作者
Li, Huafang [2 ]
Rui, Qing [1 ]
Ning, Xiaoping [3 ]
Xu, Haiyan [3 ]
Gu, Niufan [2 ]
机构
[1] Xian Janssen Pharmaceut Ltd, CNS, Med Affairs, Beijing 100025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
Long-acting injectable; Paliperidone palmitate; PANSS; Risperidone; Schizophrenia; SAFETY; EFFICACY; SCALE;
D O I
10.1016/j.pnpbp.2011.02.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia. Eligible Chinese adults (N = 452) with schizophrenia were randomized (1:1) to either PP (N = 229; deltoid injections on day 1 [150 mg eq.] and day 8 [100 mg eq.]; then once-monthly deltoid or gluteal injections, flexibly dosed [50, 100, or 150 mg eq.]). or RIS-LAI (N = 223; once-biweekly gluteal injections, flexibly dosed [25, 37.5 or 50 mg]). RIS-LAI-treated patients received oral risperidone supplementation (1-6 mg/day) at initiation and with RIS-LAI dose increases. Mean (SD) Positive and Negative Syndrome Scale (PANSS) total score at baseline was 83.2 (12.44). Mean (SD) change from baseline to endpoint in PANSS total scores (primary efficacy measure) was: -23.6 (16.28) for PP group and -26.9 (15.43) for RIS-LAI group. PP was noninferior to RIS-LAI (least squares mean difference [95% CI]: -2.3 [-5.20; 0.63]; predetermined non-inferiority margin: -5.5). Mean (SD) change from baseline to endpoint in Clinical Global Impression-Severity scale score was: -1.5 (1.24; PP group), -1.7 (1.16; RIS-LAI group) and in Personal and Social Performance Scale scores was: 16.8 (14.76; PP group), 18.6 (13.92; RIS-LAI group). The incidence of treatment-emergent adverse events (TEAEs) was similar between the two groups (73% [PP]; 75% [RIS-LAI]). The most common TEAEs were akathisia, tremor, and insomnia. The study demonstrated the noninferiority of PP (50-150 mg eq., flexibly dosed, without oral paliperidone supplementation) to risperidone-LAI (25-50 mg, flexibly dosed, with oral risperidone supplementation) for the treatment of acute schizophrenia in adult Chinese patients. PP injections were generally tolerable, and no new safety signals were detected in this population. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1002 / 1008
页数:7
相关论文
共 50 条
  • [31] Angioedema Associated With Long-Acting Injectable Paliperidone Palmitate: A Case Report
    Papadopoulou, Athanasia
    Gkikas, Kitsos
    Efstathiou, Vasiliki
    Gkikas, Ilias
    Kokoris, Styliani
    Lagari, Vasiliki
    Papageorgiou, Charalabos
    Douzenis, Athanasios
    Siafakas, Nikolaos
    Rizos, Emmanouil N.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (06) : 730 - 732
  • [32] A case of tardive dystonia associated with long-acting injectable paliperidone palmitate
    Ma, Chia-Hao
    Chien, Yi-Ling
    Liu, Chen-Chung
    Chen, I-Ming
    Lin, Chia-Hsien
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (07) : 1251 - 1252
  • [33] Use of paliperidone palmitate long-acting injectable in a patient with a personality disorder
    Martinez, N.
    Benitez Cerezo, E.
    Garcia Marin, S.
    EUROPEAN PSYCHIATRY, 2017, 41 : S714 - S714
  • [34] Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    ASIAN JOURNAL OF PSYCHIATRY, 2018, 35 : 28 - 28
  • [35] Onset of Efficacy of Long-acting Injectable Paliperidone Palmitate for Negative Symptoms and Anxiety/Depression in Subjects With Schizophrenia
    Fu, Dong-Jing
    Bossie, Cynthia A.
    Sliwa, Jennifer Kern
    Ma, Yi-Wen
    Alphs, Larry
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S511 - S512
  • [36] Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
    Such, Pedro
    Olivares, Jose Manuel
    Arias, Lizbeth
    Berg, Mette Troels
    Madera, Jessica
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 1881 - 1892
  • [37] PALIPERIDONE PALMITATE: PLACE IN THERAPY AND PRACTICAL USAGE GUIDELINES FOR A NEW LONG-ACTING INJECTABLE ANTIPSYCHOTIC
    Newton, Richard
    Damodaran, Saji
    Hustig, Harry
    Lakshmana, Raju
    Lee, Joseph
    Motamarri, Balaji
    Norrie, Peter
    Parker, Robert
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2011, 45 : A46 - A46
  • [38] A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine
    Kimura, Hiroshi
    Kanahara, Nobuhisa
    Komatsu, Naoya
    Ishige, Minoru
    Muneoka, Katsumasa
    Yoshimura, Masayuki
    Yamanaka, Hiroshi
    Suzuki, Tomotaka
    Komatsu, Hideki
    Sasaki, Tsuyoshi
    Hashimoto, Tasuku
    Hasegawa, Tadashi
    Shiina, Akihiro
    Ishikawa, Masatomo
    Sekine, Yoshimoto
    Shiraishi, Tetsuya
    Watanabe, Hiroyuki
    Shimizu, Eiji
    Hashimoto, Kenji
    Iyo, Masaomi
    SCHIZOPHRENIA RESEARCH, 2014, 155 (1-3) : 52 - 58
  • [39] Improvement in Prolactin and Sexual Side Effects in Patients With Schizophrenia Who Switched From Paliperidone Palmitate or Risperidone Long-Acting Injectable to Aripiprazole Lauroxil
    Kelly, Deanna
    Claxton, Amy
    Bidollari, Ilda
    Du, Yangchun
    Young, Matthew
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S373 - S373
  • [40] Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
    Voss, Erica A.
    Ryan, Patrick B.
    Stang, Paul E.
    Hough, David
    Alphs, Larry
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (03) : 151 - 157